The Zhitong Finance App learned that Weilizhibo-B (09887) rose more than 6%. As of press release, it had risen 6.28% to HK$36.24, with a turnover of HK$29.0492 million.

According to the news, Weilizhibo-B announced that the first case of systemic lupus erythematosus (SLE) has successfully completed the administration of the first case of systemic lupus erythematosus (SLE) with anti-dendritic cell antigen 2 (BDCA2) and the transmembrane activator and calciclophilin ligand interacting molecule (TACI), a novel bispecific fusion protein LBL-047 (known as DNTH212) in Greater China.

According to the announcement, this is the first time that LBL-047 has entered the population of patients with autoimmune diseases. The molecule acts simultaneously on two clinically proven pathogenesis pathways, innate immunity and adaptive immunity, and the LBL-047 has a complementary and differentiated dual-target design, which has been directly verified in patients for the first time.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.